drugset / Trial / NCT00612183

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

NCT00612183 ↗

Phase 2 Completed 56 enrolled SymBio Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the antitumor effects and safety of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell non-Hodgkin's lymphoma or mantle cell lymphoma.

Timeline

Start
2007-12
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 120 mg/m2 Other

Indications